Introduction
Asthma and eczema are two of the most common chronic childhood diseases in the world 1, 2 .
Asthma is an inflammatory disease of the airways with a prevalence of about 8-10% in children and 6-8% in adults in Sweden 3, 4 . Eczema, manifesting as chronic itchy flexural rashes affects about 20% of all Swedish children 2 .
Valid measures of asthma and eczema at the population level remain a challenge 5 . Most epidemiological studies investigating asthma and eczema have previously used questionnaires to identify these diseases 6 . Questionnaires are often restricted to specific areas or age-groups and can be susceptible to culture-and language-related issues associated with translation and interpretation 7, 8 . Due to ethical, economical and practical reasons a standardized clinical examination of individuals with and without asthma/eczema is not feasible in large-scale studies. Thus, validated population-based register data can function as a proxy, when aiming to study the diseases in the total population.
The Swedish National Board of Health and Welfare (NBHW) holds several population-based health registers, such as the Swedish Prescribed Drug Register (SPDR) 9 and the National Patient Register (NPR) 10 , covering the entire Swedish population (9 million inhabitants). Since July 2005, all dispensed prescriptions are reported to the SPDR. All diagnoses from the in-patient care and 75% of specialized out-patient care are reported to the NPR since 1964 and 2001 respectively, whereas diagnoses from primary health care centres (PHCC) are not recorded on a national level. To identify individuals with asthma and eczema in Sweden that have visited a physician at a PHCC, these diagnoses could be conveniently identified in the SPDR which allows identification of specific drugs for treatment of specific diseases.
Previous studies have validated asthma medication as a proxy for asthmatic disease in children [11] [12] [13] [14] and adults [14] [15] [16] by reviewing medical records from general practitioners (GPs) 12, 15, 16 or through retrospective questionnaires to GPs 11 and paediatricians 13 in limited regions. Others have suggested that prescription prevalence of asthma medication could function as a measure of disease prevalence in children 17 and adults 18 . Until now, there is no population-based study that has used randomly selected medical records on a national level to validate an asthma diagnosis with pre-defined criteria based on dispensed prescriptions of asthma medications. Some Swedish studies have already used asthma medication as a proxy for asthmatic disease [19] [20] [21] [22] , but so far no one has validated the Swedish data. Additionally, the authors have not been able to identify any study that has investigated the opportunity of using prescription data on eczema medication as a proxy for eczema.
To enhance the strength and quality of register-based research and in order to obtain generalizable findings in large populations, validation of register data is needed.
Therefore, the aim of this study was to 1) describe the utilization of asthma/eczema medication in Sweden; 2) validate if medication for asthma/ eczema can function as a proxy for an asthma/eczema diagnosis respectively, by reviewing medical records corresponding to dispensed medications in the SPDR, according to doctor-diagnoses and predefined criteria by the Swedish Paediatric Society's section for Allergy 23 ; and 3) validate asthma diagnoses in children in the NPR, by investigating how a reported diagnosis of asthma corresponds to set criteria 23 .
Method

Study design and population
This was a nationwide population-based register study using information from the SPDR, the NPR and medical records from PHCC and hospitals all around Sweden.
The SPDR is one of the largest population-based drug registers in the world 9 . It provides complete data on dispensed drugs regardless of age, gender, prescribing physician and reimbursement status. 
Collection and assessment of medical records
Random samples from all groups were sent to NBHW and PINs requested. The study participants' medical records corresponding to the dates of prescriptions of the asthma/eczema medication (aim 2), or corresponding to the discharge date from the hospital (aim 3), were requested by a letter to the head of the unit/ward where the patient had been treated. Two reminder letters were sent out before the end of data collection.
The diagnosis that each patient had been assigned by the physician at each consultation connected to the date of the prescribed medication was extracted from the medical records. Diagnoses of special interest for the asthma part were asthma (J45), acute bronchitis/bronchiolitis (J20/J21) and chronic bronchitis/chronic obstructive pulmonary disease (COPD) (J42/J44).
Furthermore, medical records belonging to pre-schoolers (0 -4.5 years) and school-age children (>4.5 -17) in the asthma medication validation and asthma diagnosis validation, were combined and reviewed by authors AÖ and CA according to the criteria of asthma set by the Swedish Paediatric Society 23 , where asthma is defined as ≥ 3 obstructive periods before two years of age and/or;; ≥ 1 obstructive period after two years of age and/or;; ≥ 1 obstructive period independent of age when the child has ≥ 1 of the following: eczema, allergy or no improvement between periods of respiratory tract infections. Children under two years of age with ≤ 2 asthma-like symptoms during respiratory tract infections, without symptoms between infections, were defined as suffering from obstructive bronchitis.
Individuals without recorded patient history (eg. only a renewal of a prescription) in any medical record were excluded in the analysis of PPV based on the criteria by the Swedish Paediatric Society.
Records in the eczema part were firstly reviewed to assess whether the child had the "umbrella diagnosis" dermatitis, which was defined as either having been assigned the diagnosis unspecific dermatitis (L30.9) by a physician or if having been given either subdiagnosis of dermatitis such as eczema (L20), allergic/non-allergic contact dermatitis (L23-L25) or seborrhoeic dermatitis (L21) assigned by the physician. Secondly, each assigned subdiagnosis of dermatitis was analysed separately.
Statistical analysis
To describe the utilization of asthma/eczema medication in Sweden, period prevalence of (incident) users that appear. The time period used for incidence estimation has to be beyond this point in time to avoid prevalent users to be included in the calculations.
To validate reported asthma/eczema medication in the SPDR as a proxy for an asthma/eczema diagnosis, positive predictive value (PPV) was estimated as the proportion of children and adults that had been given a diagnosis of asthma/eczema (as well other asthmalike and dermatitis-like diagnoses) in each medication validation group with asthma/eczema medication. PPV was also estimated as the proportion of pre-schoolers and school-age children with asthma medication that fulfilled the criteria of asthma set by the Swedish Paediatric Society. The sample size in each group was determined based on an expected PPV of 75% and aim of 95% confidence intervals of ± 5%-units.
To validate the diagnosis of asthma in children in the NPR, the proportion of children that had been given a diagnosis by a physician that fulfilled the criteria of asthma, was calculated.
Statistical Analysis Software 9.3 (SAS Institute, Cary, NC) was used for all analyses. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden. The period prevalence of drugs against eczema also decreased with increasing age. Mild glucocorticoids (GC) was the most commonly filled drug against eczema in children 0-4.5
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years, moderate GC in children >4.5-17 years and potent GC in adults. Table 2 also shows the response rates of received medical records, where the highest response rates were found in pre-schoolers (0-4.5 years: 87%) and school-age children (>4.5-17 years: 83%) in the validation of asthma diagnoses in the NPR. The lowest response rate of 66% corresponds to school-age children in the asthma medication validation.
Asthma medication as a proxy for asthma diagnosis
Reasons for no response were; 1) head of unit did not want to participate in study; 2) health care centre has ceased to exist; 3) no medical charts could be found at the unit; 4) requests were sent in return. Table 3 displays the PPV in the asthma medication validation, for a doctordiagnosis of asthma and other "asthma-like" diseases such as acute/chronic bronchitis in received medicals records. PPV for a doctor-diagnosed asthma was 89% in both school-age children (4.5-17 years) and adults (18-45), whereas PPV for pre-schoolers was 68%. The PPV for doctor-diagnosed acute bronchitis/bronchiolitis in pre-schoolers was 26%, while a PPV of less than one percent was seen for COPD/chronic bronchitis independent of age group. The groups based on type of diagnosis, are not mutually exclusive since more than one record per patient was requested, and each record was reviewed to identify the diagnosis given at each consultation.
Among pre-school children without an asthma diagnosis recorded in any medical record (n=166), approximately 38% had been given a diagnosis of acute bronchitis/bronchiolitis by their physicians. Corresponding number in school-age children was 14% (9 of 66). Three adults had been given a COPD diagnosis at one consultation, but all three had also been given a diagnosis of asthma at other occasions (not tabulated). Of the pre-school children that did not fulfil the asthma criteria, 18% (84 of 455;
after exclusion of individuals with missing information) were defined as having obstructive bronchitis by criteria, and 7% (32 of 455) as having been given asthma medication for other reasons such as cough or upper respiratory tract infections. All school-age children that did not fulfil the asthma criteria (6%) had been given a prescription for other reasons (not tabulated). Table 4 shows PPV for the "umbrella diagnosis" dermatitis and the sub-diagnoses eczema, seborrhoeic dermatitis and contact dermatitis found in medical records based on medication in the SPDR. A PPV of 82% was estimated for dermatitis, while PPV was estimated to be 45%
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for the specific diagnosis of eczema (L20). Approximately 7% (17 of 242) of the children included in the eczema medication validation were lacking information on the indication for the prescription.
Validation of asthma diagnoses in the NPR
In the validation of a asthma diagnoses in children in the NPR, about 78% of the preschoolers (0-4.5 years) fulfilled the asthma criteria set by the Swedish Paediatric Society. The ones that did not fulfil the asthma criteria were almost all defined as suffering from obstructive bronchitis (21%). In school-age children (>4.5-17 years) almost everyone (99%) fulfilled the asthma criteria (not tabulated).
Discussion
Our results show relatively high positive predictive values for asthma in all age groups which suggest that asthma medication reported in the SPDR can function as a suitable proxy for a doctor-diagnosed asthma, as well as for asthma by criteria according to the Swedish Paediatric Society. Our results bring new possibilities to study asthma in all children and young adults in Sweden and support previous findings in association studies which have used asthma medication as an indicator for asthma [19] [20] [21] [22] . Furthermore, the quality of doctordiagnosed asthma in the NPR can be considered to be high, since almost eighty percent of pre-school children and all school-age children with asthma reported in the NPR fulfilled the asthma criteria set by the Swedish Paediatric Society.
Previous studies on asthma medication as a proxy for asthmatic disease 11-16, 18, 27 have been restricted to small sample sizes 14 , specific regions 11, 13, 16 or used prescribed medications instead of filled prescriptions of medication 12, 15 . The novelty with this study is the population-based design, where randomly selected medical records on a national level have been reviewed both to assess doctor-diagnosed asthma and asthma by criteria. Concerns against asthma medication as a proxy for asthma have been that asthma medication is often prescribed to wheezing infants and the response to the drugs is used as a diagnostic tool for asthmatic symptoms 28 . Therefore, we only included individuals with at least two records of prescribed asthma medication.
In this first study to evaluate eczema medications as a proxy for a diagnosis of eczema, PPV for the "umbrella diagnosis" of dermatitis was rather high. On the other hand, the PPV estimated for an eczema diagnosis specifically was quite low. This indicates that using eczema medication as proxy for eczema may induce misclassification bias and the proxy should be used with caution. This is the first study to show population-based data on the utilization of antiasthmatic drugs in Swedish children and so far, there are no studies to our knowledge that have shown population-based data on utilization of drugs to treat eczema. Questionnairebased studies with parental reports of atopic eczema have a prevalence of approximately 20%
2 . This is a much higher number than the prescription prevalence for any investigated eczema medication in the present study. In Sweden, over-the-counter (OTC) drugs for treatment of eczema can be purchased and it is possible that children with mild symptoms might have either not been treated at all or have only used OTC drugs and are therefore not included in our data.
The main strengths of this study include our nationwide population-based study design and the randomly selected patients to be included in the review of their medical records. By using random sampling, we were able to avoid selection bias in terms of regional differences and socio-economic status affecting prescribing habits 26 . The SPDR is population-based and provides complete data. Even though our study period is limited to the start of the SPDR in 2005, we were able to avoid influences of seasonal variance.
Furthermore, the medical records in the medication validation of asthma were both reviewed in terms of doctor-diagnosis of asthma and based on criteria.
We were not able to estimate PPV for different types of asthma, which is one limitation in this study. Furthermore, our results with a lower PPV for asthma in pre-schoolers, could represent the widely recognized picture of young wheezers 31 . A diagnosis of asthma becomes more accurate with increasing age 28 and while our criteria for asthma is one of this study's strengths, it can also be questioned since it includes both children with infection-induced symptoms some of which have signs of allergy, and a group of children with allergic asthma with varying prognosis 32 . However, the obstructive symptoms for infection-induced and allergic asthma are fairly similar. Furthermore, children with infectioninduced asthma belong to the majority of children with asthma in hospital care 33 , and are important to include in a proxy for the disease to identify as many true asthmatics as possible, independent on their prognosis.
There was a slight difference in PPV between a doctor-diagnosis of asthma and asthma according to our criteria in the validation of asthma medication, which could be explained by the fact that we were able to combine information from several medical records, giving us the possibility to study the patient over time. Our values of PPV would probably have increased if we had access to medical records from other occasions than just for the consultation where a prescription was given, due to that asthma is a chronic disease and physicians might not give the patient a diagnosis at each consultation; neither prescribe medication at each visit where a diagnosis is given. The snap-shot study design can also explain why not all children with an asthma diagnosis in the NPR could be verified as asthmatics.
In the adult population, less than two percent had been given a diagnosis of COPD by their physicians, which corresponds to previous reported prevalence of COPD in young adults in the European Community Respiratory Health Survey 34 . We cannot dismiss the fact that the adults, where an indication for a prescription was missing, did not suffer from COPD. However, by excluding adults above 45 years of age, the risk that COPD has biased our results, is diminished.
In conclusion, our study suggests that asthma medication in the SPDR can be used as proxy for asthma, but not for eczema. This validation study of two Swedish registers opens for future large nation-wide register-based studies on asthma.
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